Scinai Immunotherapeutics Q3 rev. $1,049,000, down YoY.

• Scinai Immunotherapeutics reported Q3 2025 revenues of $1,049 thousand, up from $452 thousand in Q3 2024. • R&D expenses decreased to $1,799 thousand from $4,195 thousand in Q3 2024. • The growth in revenue is attributed to the expansion of Scinai Bioservices. • The decrease in R&D expenses is due to lower employee and facility costs. • The company operates a boutique CDMO business unit and is developing inflammation and immunology therapeutics.